Hepion Pharmaceuticals, Inc.
HEPA- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583771
In the last 90 days, Hepion Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $0 in total; no superinvestor holds it.
Other share classesCTRVP
13F holders, Q3 2023
Institutional positions in Hepion Pharmaceuticals, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +2 vs. Q2 2023
- Shares held
- 802.1K
- +285.0K (+55.1%) vs. Q2 2023
- Total value
- $4.00M
- −$1.43M (−26.3%) vs. Q2 2023
- New holders
- 3
- 4 more added
- Sold out
- 1
- 7 more reduced
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HEPA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 4 | $1.39K |
| Q1 2025 | 16 | $419.7K |
| Q4 2024 | 22 | $215.4K |
| Q3 2024 | 22 | $338.2K |
| Q2 2024 | 24 | $863.9K |
| Q1 2024 | 25 | $1.77M |
| Q4 2023 | 24 | $2.42M |
| Q3 2023 | 24 | $4.00M |
| Q2 2023 | 23 | $5.43M |
| Q1 2023 | 32 | $5.60M |
| Q4 2022 | 32 | $2.20M |
| Q3 2022 | 32 | $3.61M |
| Q2 2022 | 34 | $4.24M |
| Q1 2022 | 38 | $9.74M |
| Q4 2021 | 43 | $9.00M |
| Q3 2021 | 42 | $11.9M |
| Q2 2021 | 49 | $21.3M |
| Q1 2021 | 45 | $14.7M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Hepion Pharmaceuticals, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 397,607 | $1.98M | 0.06% | +397,607 | New |
| Vanguard Group Inc | 165,512 | $825.9K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 82,954 | $413.9K | 0.00% | −2,798−3.3% | Reduced |
| Octagon Capital Advisors LP | 67,500 | $336.8K | 0.06% | −87,500−56.5% | Reduced |
| Geode Capital Management, LLC | 34,909 | $174.3K | 0.00% | +34+0.1% | Added |
| State Street Corp | 15,676 | $78.2K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 14,635 | $73.0K | 0.00% | −36−0.2% | Reduced |
| Morgan Stanley | 13,077 | $65.3K | 0.00% | −10,290−44.0% | Reduced |
| Advisor Group Holdings, Inc. | 4,484 | $22.4K | 0.00% | +2,164+93.3% | Added |
| The PNC Financial Services Group, Inc. | 2,879 | $14.4K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,216 | $11.1K | 0.00% | +1,950+733.1% | Added |
| Group One Trading, L.P. | 339 | $1.69K | 0.00% | −73−17.7% | Reduced |
| Federation des caisses Desjardins du Quebec | 175 | $873 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 28 | $140 | 0.00% | +1+3.7% | Added |
| Barclays PLC | 16 | $80 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 5 | $25 | 0.00% | +5 | New |
| UBS Group AG | 2 | $10 | 0.00% | −2,669−99.9% | Reduced |
| Signaturefd, LLC | 1 | $5 | 0.00% | 00.0% | Unchanged |
| Harbor Investment Advisory, LLC | 1 | $5 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 1 | $5 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1 | $5 | 0.00% | 00.0% | Unchanged |
| Global Retirement Partners, LLC | 1 | $5 | 0.00% | +1 | New |
| Royal Bank of Canada | 82 | $0 | 0.00% | −1−1.2% | Reduced |
| Benjamin F. Edwards & Company, Inc. | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −13,359−100.0% | Sold out |
| BerganKDV Wealth Management, LLC | – | – | – | – | Not filed |